UNSPSC 51382004: Nabumetone

This classification denotes a nonsteroidal antiinflammatory drug and naphthalene compound with the molecular formula C15H16O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LW0TIW155Z, chemically known as 2-butanone, 4-(6-methoxy-2-naphthalenyl)- but generally known as nabumetone, which bears US NIH Compound Identifier 4409. European Medicines Agency schedules Nabumetone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09107MIG.

UNSPSC 51382004 Nabumetone is a Commodity code that nominally addresses a specific nonsteroidal anti-inflammatory drug, but recent state and local procurement activity under this code shows a mismatch between the code's narrow pharmaceutical designation and the actual work being solicited. The opportunities posted under this code involve broader pharmaceutical supply, naloxone procurement, and direct-to-manufacturer prescription program strategy rather than nabumetone specifically. State and local buyers using this code are acquiring pharmaceuticals and related health products through competitive bid processes, cooperative purchasing agreements, and exploratory market-intelligence phases to support community health initiatives and state employee pharmacy benefit programs. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP) serving state agencies and participating local governments across multiple jurisdictions.

The code shows recent activity concentrated in Florida, Texas, and the Upper Midwest (Minnesota, with Oregon as a participating jurisdiction in the cooperative). Representative recent opportunities include Seminole County, Florida's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually, due July 26, 2023, with quarterly deliveries and fixed-fee pricing; the Texas HHS Commission's RFI on a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, due April 3, 2026, seeking vendor capabilities for direct contracting with self-insured employers and state agencies; and MMCAP's RFP to establish multiple contracts for generic multi-source pharmaceuticals and OTC products, due March 26, 2026, with awards effective July 1, 2026, requiring vendors to work through authorized wholesalers and comply with cGMP and DSCSA certification. The code shows limited relevant recent activity, and the mismatch between the code's nominal scope (nabumetone) and actual solicitation content (naloxone, generic pharmaceuticals, and pharmacy program strategy) suggests this code is not the primary vehicle for state and local pharmaceutical procurement.